Sonoma Pharmaceuticals (SNOA) Total Debt Growth (5y) (2016 - 2026)
Sonoma Pharmaceuticals (SNOA) Total Debt Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.06% |
| Mar 31, 2026 | -34.95% |
| Sep 30, 2025 | -47.16% |
| Jun 30, 2025 | -38.46% |
| Mar 31, 2025 | -14.48% |
| Sep 30, 2024 | -5.00% |
| Jun 30, 2024 | -0.67% |
| Mar 31, 2024 | -0.67% |
| Dec 31, 2023 | 14.87% |
| Sep 30, 2023 | 11.68% |
| Jun 30, 2023 | 6.18% |
| Mar 31, 2023 | 10.47% |
| Dec 31, 2022 | -20.42% |
| Sep 30, 2022 | 22.63% |
| Jun 30, 2022 | 29.73% |
| Mar 31, 2022 | 32.57% |
| Dec 31, 2021 | 57.80% |
| Sep 30, 2021 | 49.73% |
| Jun 30, 2021 | 81.78% |
| Mar 31, 2021 | 75.65% |